Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host interferon signaling proteins encompass a diverse group of host cell proteins that mediate the intracellular effects of interferon cytokines, which include type I (IFN-α, IFN-β), type II (IFN-γ), and type III (IFN-λ) interferons[3][4][7]. Following interferon receptor engagement by interferon ligands, these proteins include: - Cytokine receptors (e.g., IFNAR1/2, IFNGR1/2, IFNLR1, IL-10R2), which bind interferons on the cell surface and initiate signaling[4][7][8]. - Janus kinases (e.g., JAK1, JAK2, TYK2), which are associated with the cytoplasmic domains of receptors and become activated upon ligand binding, phosphorylating downstream signal transducers[1][2][6][8]. - Signal transducer and activator of transcription (STAT) proteins (e.g., STAT1, STAT2), which, once phosphorylated, dimerize and translocate to the nucleus to regulate transcription of interferon-stimulated genes (ISGs) critical for antiviral and immunomodulatory responses[1][2][3][7]. - Additional molecules involved in noncanonical signaling, such as MAP kinases, PI3K, and regulatory adaptor proteins (e.g., CRKL), further diversify the signaling outputs[1][8]. Dysregulation of these signaling proteins broadly impacts innate and adaptive immunity, contributing to susceptibility to infections, chronic inflammation, autoimmunity, and cancer[3][5][7]. Because the term does not specify a single protein but rather a set of molecular participants in the interferon-signaling pathway, it is not conventionally considered a singular "therapeutic target" but a major immune signaling system. For structured target-based research, the analysis must be narrowed to specific interferon receptors (e.g., "Interferon alpha/beta receptor 1") or key mediators (e.g., "Janus kinase 1", "Signal transducer and activator of transcription 1")[1][2][4][6][8].
Activation of JAK-STAT pathway, Modulation of immune gene expression, Inhibition of viral replication, Upregulation of antigen presentation
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host interferon signaling proteins.